NCT04794569View on ClinicalTrials.gov

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

PHASE4TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Deep Vein ThrombosisPost Thrombotic Syndrome
Interventions
DRUG

tinzaparin

low molecular weight heparin

DRUG

Rivaroxaban

direct oral anticoagulant

Trial Locations (5)

L8L 2X2

Hamilton General Hospital, Hamilton

L8V 1C3

Juravinski Hospital and Cancer Centre, Hamilton

H3T 1E2

Sir Mortimer B. Davis Jewish General Hospital, Montréal

Unknown

The Ottawa Hospital - Ottawa Hospital Research Institute (OHRI), Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

collaborator

Sunnybrook Research Institute

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER